Conference Description:

Enhancing the Development and Bringing to Market of New Dermatological Therapeutic Options

Returning as a virtual event for the 4th year, Dermatology Drug Development Summit is the only industry-focused meeting dedicated to innovating, accelerating, and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs, in the treatment of high unmet need.

Join this exclusive dermatology drug development community to network and learn from the leading experts in pharma, biotech and academia, to debate the end-to-end challenges in dermatology drug development: from discovering new research on key disease pathways, to unveiling critical preclinical insights, discussing formulation strategies, defining the optimal clinical development plans or evaluating commercialization approaches.

Navigate across 3 full days packed with dedicated, interactive formats to enhance the development and bringing to market of new dermatological therapeutic options, including a range of interactive workshops.

Discover how dermatology lends itself well to virtual clinical trials, the future of drug development in dermatology and the changing role of clinical and medical professionals during COVID-19.

Tickets:https://go.evvnt.com/670445-0? pid=154

Prices:
Conference + 2 Workshops (Industry): USD 2902.0,
Conference + 1 Workshop (Industry): USD 2483.0,
Conference Only (Industry): USD 2064.0,
Individual Workshop: USD 524.0

Speakers: Alan Menter Dermatologist Texas Dermatology Associates, Ana Beatris Rossi Global Senior Director, Medical, Immunology, Dermatology and Dupilumab Sanofi, Bola Akinlade Vice President of Clinical Sciences, Inflammation and Immunology Regeneron, Brett King Associate Professor of Dermatology University of Yale School of Medicine, Brian Kim Co-Director, Center for the Study of Itch and Associate Professor - Medicine, Anesthesiology, Pathology and Immunology Washington University School of Medicine in St. Louis, Christine Janus Chief Executive Officer GlobalSkin, Dan Kaplan Professor of Dermatology and Immunology University of Pittsburgh, Dirk Brockstedt Chief Scientific Officer RAPT Therapeutics, Elena Rizova Vice President and Head of Medical Affairs Immune Inflammation, Dupilumab and Atopic Dermatitis Sanofi, Emma Guttman- Yassky Vice Chair for Research, Department of Dermatology, Professor of Dermatology and Immunology Icahn School of Medicine at Mount Sinai, Eric Simpson Professor of Dermatology Oregon Health and Science University Gaines Hall, Fiona Kuo Director of Clinical Science Incyte Corporation, James Cassella Chief Development Officer Concert Pharmaceuticals, Jasmina Jankicevic Dermatologist, Clinical Development and Medical Affairs and Consultant Jasmina Jankicevic Consulting, Jaymin Shah Research Fellow Pfizer, Jennifer Good President and Chief Executive Officer Trevi Therapeutics, John Armstrong Head of Discovery Strategic Therapeutic Galderma, John Harris Associate Professor of Dermatology Dermatology University of Massachusetts Medical School, Joslyn Sciacca Kirby Associate Professor of Dermatology Penn State University in Hershey, John Zibert Chief Medical Officer LEO Pharma, Julie Block Chief Executive Officer and President National Eczema Association (NEA), Jun Lu Associate Professor and Director - Clinical Research University of Connecticut, Kendall Marcus Director, Division of Dermatology and Dental Products Division of Dermatology and Dental Products FDA, Kim Kjoeller Executive Vice President - Research and Development LEO Pharma, Leon Kircik Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai, Lotus Mallbris Vice President and Global Head of Immunology Product Development Eli Lilly, Lourdes Maria Perez Chada Clinical Research Fellow Brigham and Women's Hospital, Mandeep Kaur Vice President and Head of Medical Affairs and Dupixent Sanofi, Mark Feitelson Chief Scientific Officer and Professor SFA Therapeutics and Temple University, Mary Spellman Chief Medical Officer Castle Creek Pharma, Michael Howell Senior Director, Translational Research Incyte Corporation, Michael Wachs Chief Scientific Officer Attillaps Pharmaceuticals, Misha Rosenbach Associate Professor of Dermatology University of Pennsylvania, Peter Lio Clinical Assistant Professor of Dermatology and Paediatrics North Western University, Feinberg School of Medicine, Philippe Diaz Co-Founder and Chief Scientific Officer Dermaxon, Rasmus Hogreffe Head of Virtual Clinical Trial LEO Innovation Lab, Stephan Weidinger Professor - Department of Dermatology University of Kiel, Sylvie Gabriel Head of Global Market Access, Health Economics, Reimbursement and Pricing Galderma Laboratories, Victoria Werth Professor of Dermatology University of Pennsylvania, Paul Lizzul Executive Medical Director - Global Development Lead - Inflammation Amgen

Time: 9:00 am to 6:00 pm